Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy

Journal of the College of Physicians and Surgeons Pakistan

Volumn 21, Issue 11, 2011, Pages 666-671

  Abid, Shahab ^a   Jafri, Wasim ^a   Mumtaz, Khalid ^a   Islam, Muhammad ^a   Abbas, Zaigham ^a   Shah, Hasnain Ali ^a   Hamid, Saeed ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Hepatic encephalopathy; L ornithine L aspartate; Liver cirrhosis

Indexed keywords

AMMONIA; ANTIBIOTIC AGENT; CREATININE; LACTULOSE; METRONIDAZOLE; ORNITHINE ASPARTATE; PLACEBO; POTASSIUM; SODIUM CHLORIDE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PERITONITIS; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DISEASE ASSOCIATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; HYPOKALEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUMBER CONNECTION TEST A; PAKISTAN; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS BACTERIAL PERITONITIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GLUCOSE; HEPATIC ENCEPHALOPATHY; HUMANS; INFUSIONS, INTRAVENOUS; LACTULOSE; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856048480     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Groeneweg M, Moerland W, Quero JC, Hop WCJ, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. J Hepatol 2000; 32:748-53.
2. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004; 19:253-67.
3. Conn HO. The hepatic encephalopathies. In: Conn HO, Bircher J, editors. Hepatic encephalopathy: syndromes and therapies. Illinois: Medi-Ed Press; 1994. p. 1-12.
4. Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis, and management. Drugs 2000; 60:1353-70.
5. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122-8.
6. Rink CH, Heating J, Nilius R. Prognosis assessment in patients with liver cirrhosis. Hepatogastroenterology 1990; 37:514.
7. Shawcross DL, Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005; 20:169-79.
8. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002; 14:221-7.
9. Kircheis G, Häussinger D. Management of hepatic encephalopathy. J Gastroenterol Hepatol 2002; 17:S260-7.
10. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systemic review of randomised trials. BMJ 2004; 328:1046-50. Epub 2004 Mar 30.
11. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, et al. L-ornithine L-aspartate in experimental portosystemic encephalopathy: therapeutic efficacy and mechanisms of action. Metab Brain Dis 1998; 13:147-57.
12. Rees CJ, Hudson M, Record CO. Therapeutic modalities in portal hypertension. Eur J Gastroenterol Hepatol 1997; 9:9-11.
13. Ndraha S, Simadibrata M. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy. Acta Med Indones 2010; 42:158-61.
14. A critical analysis of studies assessing L-Lornithine-L-aspartate (LOLA) in hepatic encephalopahty treatment. Arq Gasroenterol 2009; 46:241-7.
15. Acharya SK, Bhatia V, Sreenivas V, Khanai S, Panda SK. Efficacy of L-ornithine L-aspartae in acute liver failure: a doubleblind, randomized, placebo-controlled study. Gastroenterology 2009; 136:2159-68.
16. Kircheis G, Wettstein M, Vom Dahl S, Häussinger D. Clinical efficacy of L-ornithine-l-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002; 17:453-62.
17. Conn HO. Quantifying the severity of hepatic encephalopathy. In: Conn HO, Bircher J, editors. Hepatic encephalopathy: syndromes and therapies. Illinois: Medi-Ed Press; 1994. p. 13-26.
18. Conn HO. Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22:541-50.
19. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-21.
20. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114:188-93
21. Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis 2004; 19:345-9.
22. Schmid M, Peck-Radosvjevic M, Konig F, Mittermaire C, Gangly A, Ferenci P. A double-blind, randomized placeo -controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010; 30:574-82.
23. Ahmed I, Khan AA, Alam A, Dilshad A, Butt AK, Shafqat F, et al. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg Pak 2008; 18:684-7.
24. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-Laspartate in the management of hepatic encephalopahty: a meta-analysis. J Gastroenteol Hepatol 2009; 24:9-14. Epub 2008 Sep 24.